{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:23:23Z","timestamp":1777184603100,"version":"3.51.4"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.amjmed.2017.03.002","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T19:01:51Z","timestamp":1490641311000},"page":"862.e1-862.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies"],"prefix":"10.1016","volume":"130","author":[{"given":"David A.","family":"Hanley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Shawn","family":"Davison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Dian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve T.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Michael","family":"Lewiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.amjmed.2017.03.002_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/13697137.2015.1099806","article-title":"The role of menopausal hormone therapy in the management of osteoporosis","volume":"18","author":"de Villiers","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.amjmed.2017.03.002_bib2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2017.03.002_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2017.03.002_bib4","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2017.03.002_bib5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib6","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2017.03.002_bib7","article-title":"Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension Trial","volume":"30","author":"Bone","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.amjmed.2017.03.002_bib8","first-page":"1","article-title":"Osteoporosis prevention, diagnosis and therapy","volume":"17","year":"2000","journal-title":"NIH Consens Statement"},{"key":"10.1016\/j.amjmed.2017.03.002_bib9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2017.03.002_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A\u00a0randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib11","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2017.03.002_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib13","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2017.03.002_bib17","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2017.03.002_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","article-title":"Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis","volume":"74","author":"Harrington","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib19","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib23","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib24","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2017.03.002_bib25","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI113523","article-title":"Age and bone mass as predictors of fracture in a prospective study","volume":"81","author":"Hui","year":"1988","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.amjmed.2017.03.002_bib26","first-page":"346","article-title":"Alendronate and risedronate: reports of severe bone, joint, and muscle pain","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00198-014-2872-5","article-title":"Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial","volume":"26","author":"Patel","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ophtha.2012.10.028","article-title":"The incidence of acute anterior uveitis after intravenous zoledronate","volume":"120","author":"Patel","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.amjmed.2017.03.002_bib29","doi-asserted-by":"crossref","first-page":"E431","DOI":"10.1503\/cmaj.111752","article-title":"Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study","volume":"184","author":"Etminan","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.amjmed.2017.03.002_bib30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1572-0241.2000.01835.x","article-title":"Upper gastrointestinal toxicity of alendronate","volume":"95","author":"Lowe","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2017.03.002_bib31","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1365-2036.2000.00864.x","article-title":"A\u00a0randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract","volume":"14","author":"Marshall","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2017.03.002_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","article-title":"Pharmacology of bisphosphonates","volume":"49","author":"Cremers","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2017.03.002_bib33","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib34","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib35","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib36","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJMc1403799","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"371","author":"Schilcher","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib37","first-page":"986718","article-title":"Acute nontraumatic clavicle fracture associated with long-term bisphosphonate therapy","volume":"2014","author":"Vun","year":"2014","journal-title":"Case Rep Orthop"},{"key":"10.1016\/j.amjmed.2017.03.002_bib38","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/ans.12536","article-title":"Delayed\/non-union of upper limb fractures with bisphosphonates: systematic review and recommendations","volume":"84","author":"Ng","year":"2014","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.amjmed.2017.03.002_bib39","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00198-013-2428-0","article-title":"Can long-term bisphosphonate use causes low-energy fractures? A case report","volume":"25","author":"Dandinoglu","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib40","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/jbmr.1593","article-title":"Low-energy fractures of the humeral shaft and bisphosphonate use","volume":"27","author":"Yavropoulou","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib41","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib42","doi-asserted-by":"crossref","first-page":"i3365","DOI":"10.1136\/bmj.i3365","article-title":"Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study","volume":"353","author":"Abrahamsen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2017.03.002_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1148\/radiol.13122691","article-title":"Detection of prefracture hip lesions in atypical subtrochanteric fracture with dual-energy x-ray absorptiometry images","volume":"270","author":"Kim","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.amjmed.2017.03.002_bib45","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14219\/jada.archive.2008.0017","article-title":"Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial","volume":"139","author":"Grbic","year":"2008","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.amjmed.2017.03.002_bib47","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.amjmed.2017.03.002_bib48","first-page":"75","article-title":"Decreased risk of breast cancer associated with oral bisphosphonate therapy","volume":"4","author":"Mathew","year":"2012","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.amjmed.2017.03.002_bib49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.2012.42.9530","article-title":"Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis","volume":"31","author":"Thosani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.amjmed.2017.03.002_bib50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jbmr.1481","article-title":"Esophageal and gastric cancer incidence and mortality in alendronate users","volume":"27","author":"Abrahamsen","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib51","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00198-012-1894-0","article-title":"A\u00a0population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke","volume":"23","author":"Kang","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00198-012-2213-5","article-title":"Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study","volume":"24","author":"Kang","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib53","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib54","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jbmr.2767","article-title":"Mortality after atypical femoral fractures: a cohort study","volume":"31","author":"Kharazmi","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib55","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis\u2014where do we go from here?","volume":"366","author":"Whitaker","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2017.03.002_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2017.03.002_bib57","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00198-015-3355-z","article-title":"Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review","volume":"27","author":"Selga","year":"2016","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.amjmed.2017.03.002_bib58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00774-014-0606-6","article-title":"Atypical femoral fracture in a patient treated with denosumab","volume":"33","author":"Khow","year":"2015","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.amjmed.2017.03.002_bib59","first-page":"249872","article-title":"An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab","volume":"2013","author":"Villiers","year":"2013","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.amjmed.2017.03.002_bib60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/17453674.2014.885355","article-title":"Atypical fracture of the femur in a patient using denosumab\u2014a case report","volume":"85","author":"Schilcher","year":"2014","journal-title":"Acta Orthop"},{"key":"10.1016\/j.amjmed.2017.03.002_bib61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2013.12.027","article-title":"Bilateral atypical femoral fractures in a patient prescribed denosumab \u2013 a case report","volume":"61","author":"Thompson","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2017.03.002_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/17453674.2013.854668","article-title":"Atypical femoral fractures bilaterally in a patient receiving denosumab","volume":"85","author":"Drampalos","year":"2014","journal-title":"Acta Orthop"},{"key":"10.1016\/j.amjmed.2017.03.002_bib63","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.4158\/EP12367.CR","article-title":"A\u00a0case of an unusual subtrochanteric fracture in a patient receiving denosumab","volume":"19","author":"Paparodis","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.amjmed.2017.03.002_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.amjmed.2017.03.002_bib65","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib66","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib67","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2017.03.002_bib71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.amjmed.2017.03.002_bib72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/cen.13012","article-title":"Changes in bone mineral density and bone turnover in patients on \u2018drug holiday\u2019 following bisphosphonate therapy: real-life clinic setting","volume":"84","author":"Roberts","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.amjmed.2017.03.002_bib73","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2015-3156","article-title":"Underdiagnosis and undertreatment of osteoporosis: the battle to be won","volume":"101","author":"Miller","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2017.03.002_bib74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-007-0483-0","article-title":"The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study","volume":"19","author":"Papaioannou","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2017.03.002_bib75","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00198-010-1359-2","article-title":"Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study","volume":"22","author":"Fraser","year":"2011","journal-title":"Osteoporos Int"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934317302620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934317302620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:11:21Z","timestamp":1757581881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934317302620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0002934317302620"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.03.002","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}